{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:37:08Z","timestamp":1791873428259,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00595-025-03227-3","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T18:40:43Z","timestamp":1767638443000},"page":"1158-1168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-1103","authenticated-orcid":false,"given":"Michinori","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Tsunematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Yugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenei","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Haruki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Taniai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Yanagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoga","family":"Hamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Uwagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Okui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Tanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munetoshi","family":"Akaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Yoshizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"3227_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"3227_CR2","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1053\/j.gastro.2009.02.038","volume":"136","author":"JE Everhart","year":"2009","unstructured":"Everhart JE, Ruhl CE. Burden of digestive diseases in the united States part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136:1134\u201344.","journal-title":"Gastroenterology"},{"key":"3227_CR3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00595-020-02031-5","volume":"50","author":"T Noji","year":"2020","unstructured":"Noji T, Nagayama M, Imai K, Kawamoto Y, Kuwatani M, Imamura M, et al. Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study. Surg Today. 2020;50:1409\u201317.","journal-title":"Surg Today"},{"key":"3227_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00595-024-02912-z","volume":"55","author":"H Kosaka","year":"2025","unstructured":"Kosaka H, Matsui K, Ikeura T, Ito T, Ohe C, Kono Y, et al. Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancers. Surg Today. 2025;55:351\u20139.","journal-title":"Surg Today"},{"key":"3227_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"3227_CR6","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30:1950\u20138.","journal-title":"Ann Oncol"},{"key":"3227_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30:102\u201310.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"3227_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1:EVIDoa2200015.","journal-title":"NEJM Evidence"},{"key":"3227_CR9","doi-asserted-by":"publisher","first-page":"1079074","DOI":"10.3389\/fendo.2023.1079074","volume":"14","author":"Y Iwamoto","year":"2023","unstructured":"Iwamoto Y, Kimura T, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, et al. Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer. Front Endocrinol. 2023;14:1079074.","journal-title":"Front Endocrinol"},{"key":"3227_CR10","doi-asserted-by":"publisher","first-page":"1221723","DOI":"10.3389\/fendo.2023.1221723","volume":"14","author":"Y Iwamoto","year":"2023","unstructured":"Iwamoto Y, Kimura T, Dan K, Ohnishi M, Takenouchi H, Iwamoto H, et al. Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects. Front Endocrinol. 2023;14:1221723.","journal-title":"Front Endocrinol"},{"key":"3227_CR11","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","volume":"71","author":"YM Cheung","year":"2022","unstructured":"Cheung YM, Wang W, McGregor B, Hamnvik OR. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022;71:1795\u2013812.","journal-title":"Cancer Immunol Immunother"},{"key":"3227_CR12","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"3227_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3227_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16727-w","volume":"12","author":"D Liu","year":"2022","unstructured":"Liu D, Heij LR, Czigany Z, Dahl E, Dulk MD, Lang SA, et al. The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis. Sci Rep. 2022;12:12691.","journal-title":"Sci Rep"},{"key":"3227_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cca.2017.09.006","volume":"474","author":"LH Zhou","year":"2017","unstructured":"Zhou LH, Luo XF. Platelet to lymphocyte ratio in biliary tract cancer: review and meta-analysis. Clin Chim Acta. 2017;474:102\u20137.","journal-title":"Clin Chim Acta"},{"key":"3227_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1245\/s10434-020-08728-8","volume":"28","author":"J Wang","year":"2021","unstructured":"Wang J, Bo X, Li M, Nan L, Wang C, Gao Z, et al. Prediction efficacy for clinical outcome of prognostic nutritional index in patients with resectable biliary tract cancer depends on sex and obstructive jaundice status. Ann Surg Oncol. 2021;28:430\u20138.","journal-title":"Ann Surg Oncol"},{"key":"3227_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.gassur.2024.01.023","volume":"28","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Liu Z, Cheng Y, Li J, Fu W. Prognostic value of the modified Glasgow prognostic score in biliary tract cancer patients: a systematic review and meta-analysis. J Gastrointest Surg. 2024;28:559\u201365.","journal-title":"J Gastrointest Surg"},{"key":"3227_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1245\/s10434-013-3292-z","volume":"21","author":"XS Wu","year":"2014","unstructured":"Wu XS, Shi LB, Li ML, Ding Q, Weng H, Wu WG, et al. Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma. Ann Surg Oncol. 2014;21:449\u201357.","journal-title":"Ann Surg Oncol"},{"key":"3227_CR19","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.clnu.2018.12.004","volume":"38","author":"S Yao","year":"2019","unstructured":"Yao S, Kaido T, Okumura S, Iwamura S, Miyachi Y, Shirai H, et al. Bone mineral density correlates with survival after resection of extrahepatic biliary malignancies. Clin Nutr. 2019;38:2770\u20137.","journal-title":"Clin Nutr"},{"key":"3227_CR20","doi-asserted-by":"publisher","first-page":"15217","DOI":"10.1002\/cam4.6209","volume":"12","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang D, Yang L, Zhao L, Yang L, Zhang J, et al. Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors. Cancer Med. 2023;12:15217\u201328.","journal-title":"Cancer Med"},{"key":"3227_CR21","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.21873\/anticanres.14264","volume":"40","author":"R Tanaka","year":"2020","unstructured":"Tanaka R, Kimura K, Eguchi S, Tauchi J, Shibutani M, Shinkawa H, et al. Preoperative neutrophil-to-lymphocyte ratio predicts tumor-infiltrating CD8(+) T cells in biliary tract cancer. Anticancer Res. 2020;40:2881\u20137.","journal-title":"Anticancer Res"},{"key":"3227_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584423","volume":"11","author":"N Principe","year":"2020","unstructured":"Principe N, Kidman J, Goh S, Tilsed CM, Fisher SA, Fear VS, et al. Tumor infiltrating effector memory antigen-specific CD8(+) T cells predict response to immune checkpoint therapy. Front Immunol. 2020;11:584423.","journal-title":"Front Immunol"},{"key":"3227_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41598-024-84488-9","volume":"15","author":"Y Iwamoto","year":"2025","unstructured":"Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y, et al. Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients. Sci Rep. 2025;15:390.","journal-title":"Sci Rep"},{"key":"3227_CR24","doi-asserted-by":"publisher","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","volume":"7","author":"S Cook","year":"2024","unstructured":"Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, et al. Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw Open. 2024;7:e2352302.","journal-title":"JAMA Netw Open"},{"key":"3227_CR25","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.3390\/cancers14163878","volume":"14","author":"N Guezour","year":"2022","unstructured":"Guezour N, Soussi G, Brosseau S, Abbar B, Naltet C, Vauchier C, et al. Grade 3\u20134 immune-related adverse events induced by immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) patients are correlated with better outcome: a real-life observational study. Cancers. 2022; 14: 3878.","journal-title":"Cancers"},{"key":"3227_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf148","author":"L Antonuzzo","year":"2025","unstructured":"Antonuzzo L, Takahashi H, Park JO, Sookprasert A, Gillmore R, Yang SS, et al. Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyaf148.","journal-title":"Oncologist"},{"key":"3227_CR27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662\u201380.","journal-title":"Nat Rev Cancer"},{"key":"3227_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.","journal-title":"Nature"},{"key":"3227_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41590-024-01789-x","volume":"25","author":"Y Xia","year":"2024","unstructured":"Xia Y, Li X, Bie N, Pan W, Miao YR, Yang M, et al. A method for predicting drugs that can boost the efficacy of immune checkpoint blockade. Nat Immunol. 2024;25:659\u201370.","journal-title":"Nat Immunol"},{"key":"3227_CR30","doi-asserted-by":"publisher","first-page":"1141148","DOI":"10.3389\/fimmu.2023.1141148","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang X, Li Y, Hong Y, Zhao Q, Ye Z. Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: a retrospective cohort study. Front Immunol. 2023;14:1141148.","journal-title":"Front Immunol"},{"key":"3227_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01546-4","volume":"15","author":"C Zhao","year":"2024","unstructured":"Zhao C. Correlation between thyroid dysfunction and efficacy of immune checkpoint inhibitors in patients with advanced solid tumors. Discover Oncol. 2024;15:663.","journal-title":"Discover Oncol"},{"key":"3227_CR32","doi-asserted-by":"publisher","first-page":"16501","DOI":"10.1007\/s00432-023-05364-z","volume":"149","author":"Y Lu","year":"2023","unstructured":"Lu Y, Li Q, Xu L, Zheng Y, Wang Y, Liu Y, et al. Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma. J Cancer Res Clin Oncol. 2023;149:16501\u201310.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-03227-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-025-03227-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-03227-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:56:16Z","timestamp":1782395776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-025-03227-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1007\/s00595-025-03227-3","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest for any of the authors except for TY, who received lecture fees from AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the suitably constituted ethics committee of our institution and conforms to the provisions of the Declaration of Helsinki [the Ethics Committee of Jikei University School of Medicine (Tokyo, Japan), Approval No. 36\u2013322 (12435); the Ethics Committee of Kyushu University (Fukuoka, Japan), Approval No. M25002].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of the research protocol"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration number of the study"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}}]}}